New pill aims to tame seizures in rare brain disorders
NCT ID NCT07287202
First seen Jan 07, 2026 · Last updated May 07, 2026 · Updated 18 times
Summary
This early-stage trial tests an oral drug called SVG103 (paxalisib) in 15 adults with rare brain conditions (FCD-II, TSC, or HME) that cause hard-to-control seizures. The main goal is to see if the drug is safe and tolerable, with a secondary look at whether it reduces seizure frequency. Participants will take the drug long-term after an initial safety period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS COMPLEX (TSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, Victoria, 3084, Australia
-
The Alfred
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.